ArticleMethods in molecular biology (Clifton, N.J.)2023
Statistical and Computational Methods for Proteogenomic Data Analysis.
Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteins are the functional molecules for almost all cellular and biological processes. They are also the targets of most drugs. Proteins employ complex, multilevel regulations, so their abundance levels do not well correlated with their mRNA expression levels. The structure, activity, and functional roles of proteins are affected by posttranslational modifications (PTM), which are even less correlated with mRNA expression levels than protein abundances. Comprehensive characterization of the proteomics data is critical for understanding the molecular and cellular mechanisms of biological systems and developing news therapeutics. Current large-scale proteomic profiling technologies, such as mass spectrometry, provide relative identification of peptides and proteins, with data vulnerable to outliers, batch effects, and nonrandom missingness. In order to perform high-quality proteomic data analysis, we will first introduce a data preprocessing and quality control pipeline that includes normalization, outlier detection and removal, batch effect identification and handling, and missing data imputation. Then, we will describe several statistical methods that leverage well-processed proteomic data to generate scientific discoveries, especially with an integration with genomics and transcriptomics. These methods cover topics like association analysis, network construction, clustering, and cell-type deconvolution. To demonstrate these methods, we will use the proteogenomic data from the lung squamous cell carcinoma study of the Clinical Proteomic Tumor Analysis Consortium and provide sample codes for data access and analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.